Letrozole with temozolomide for recurrent high grade glioma

You may qualify if

• Radiographically, histologically or cytologically confirmed recurrent brain high grade glioma with plan for resection or biopsy.; Inclusion #1 for Sub-study Only: Radiographically, histologically or cytologically confirmed recurrent brain high grade glioma.
• Age >18 years.
• ECOG performance status 0 -2 (Karnofsky >60%, see Appendix A).
• CBC/differential obtained within 28 days prior to registration on study, with adequate bone marrow function defined as follows:; Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3;; Platelets ≥ 100,000 cells/mm3;; Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable).
• Adequate hepatic function, defined as follows:; Total bilirubin < 2 x institutional ULN within 14 days prior to registration;; AST or ALT < 3 x institutional ULN within 14 days prior to registration.
• Adequate renal function, defined as GFR > 30 ml/min or Cr < 1.5.
• Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential.
• Imaging prior to treatment including MRI of brain (with contrast preferred but not required).
• Ability to understand and the willingness to sign a written informed consent document.
• Inclusion #10 for Sub-study Only: Measurable disease per RANO criteria within 28 days of starting treatment on this study.

You can't join if

• Patients may not be receiving any other investigational agents.
• History of allergic reactions attributed to letrozole or other agents used in study. Exclusion #2 for Sub-study Only: History of allergic reactions attributed to letrozole or TMZ.
• Uncontrolled intercurrent illness including, but not limited to, ongoing significant or serious active cardiovascular disease (CHF exacerbation, unstable angina or MI in last 6 months), or infection including the diagnosis of AIDS or active hepatitis B or C infection, or psychiatric illness or medical or personal conditions that in the opinion of the investigator would limit the patient's ability to participate.
• Patients attempting to conceive, and pregnant or nursing women are excluded from this study.